Wang Jing, Ni Xiang-Zhi, Yang Ming-Lei, Huang Xing, Hou Shu-Ming, Peng Cheng, Cao Jia-Shi, Liu Tie-Long
Department of Orthopaedic Oncology, Spinal Tumor Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Front Oncol. 2023 Mar 1;13:1083776. doi: 10.3389/fonc.2023.1083776. eCollection 2023.
Spinal osteosarcoma is a rare osseous neoplasm. The aim of this study is to make a comprehensive analysis of the demographic features, clinicopathologic characteristics and factors affecting prognosis of spinal osteosarcoma using the Surveillance, Epidemiology and End Results (SEER) database.
SEER data were reviewed to identify patients diagnosed with spinal osteosarcoma between 1975 and 2016 and determine their overall survival (OS) and disease-specifc survival (DSS). Univariate and multivariate analyses were performed using the Cox-regression proportional hazards model and Kaplan-Meier method.
A total of 668 patients (53.1% males) with spinal osteosarcoma were identified. The mean age at diagnosis was 45.2 years, including 67.5% patients younger than 60 years. The median OS of these patients was 15 months, and the 5-year OS was 16.8%. Multivariate analysis showed that age ≥60 year (HR=2.271, p = 0.008), high grade (HR=1.323, p = 0.008), regional stage (HR=1.658, p = 0.017), metastasis stage (HR=3.045, p < 0.001) and no-surgery treatment (HR=1.761, p < 0.001) were adversely associated with OS; gender (HR=0.657, p = 0.044), tumor grade (HR=1.616, p = 0.006), tumor stage (HR=3.329, p = 0.011; HR=7.983, p < 0.001) and radiotherapy (HR=0.606, p = 0.031) were independent prognostic factors affecting DSS.
Based on SEER data analysis, male, high tumor grade, regional stage, metastasis stage and radiotherapy are independent predictors of poor survival of patients with spinal osteosarcoma. The clinical treatment of spinal osteosarcoma still faces serious challenges. Future research should focus on the clinical impact and survival outcomes of the emerging targeted and immune therapies for the sake of improving the survival stalemate of spinal osteosarcoma.
脊柱骨肉瘤是一种罕见的骨肿瘤。本研究旨在利用监测、流行病学和最终结果(SEER)数据库,对脊柱骨肉瘤的人口统计学特征、临床病理特征及影响预后的因素进行综合分析。
回顾SEER数据,以确定1975年至2016年间诊断为脊柱骨肉瘤的患者,并确定其总生存期(OS)和疾病特异性生存期(DSS)。使用Cox回归比例风险模型和Kaplan-Meier方法进行单因素和多因素分析。
共识别出668例脊柱骨肉瘤患者(男性占53.1%)。诊断时的平均年龄为45.2岁,其中67.5%的患者年龄小于60岁。这些患者的中位OS为15个月,5年OS为16.8%。多因素分析显示,年龄≥60岁(HR=2.271,p = 0.008)、高级别(HR=1.323,p = 0.008)、区域分期(HR=1.658,p = 0.017)、转移分期(HR=3.045,p < 0.001)和未接受手术治疗(HR=1.761,p < 0.001)与OS呈负相关;性别(HR=0.657,p = 0.044)、肿瘤分级(HR=1.616,p = 0.006)、肿瘤分期(HR=3.329,p = 0.011;HR=7.983,p < 0.001)和放疗(HR=0.606,p = 0.031)是影响DSS的独立预后因素。
基于SEER数据分析,男性、高肿瘤分级、区域分期、转移分期和放疗是脊柱骨肉瘤患者生存不良的独立预测因素。脊柱骨肉瘤的临床治疗仍面临严峻挑战。未来的研究应关注新兴靶向和免疫治疗的临床影响及生存结果,以改善脊柱骨肉瘤的生存僵局。